Liothyronine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Liothyronine is a synthetic form of triiodothyronine (T3), the most metabolically active thyroid hormone. It has a faster onset and shorter duration than levothyroxine and is sometimes used in combination with T4, for T3-only therapy in select cases, or for short-term TSH suppression in thyroid cancer diagnostic protocols. It is not considered first-line treatment for hypothyroidism.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Liothyronine is a synthetic form of triiodothyronine (T3), the most metabolically active thyroid hormone. NutriStack rates the supporting evidence as moderate. Common adult dosing is 5–75 mcg daily in divided doses; combination therapy typically 5–15 mcg daily (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
- Tachycardia and palpitations
- Tremor
- Insomnia and nervousness
- Untreated adrenal insufficiency
- Acute myocardial infarction (unless hypothyroidism is contributory)
The bottom line
Evidence rating moderate. Most-documented uses: rapid onset of thyroid hormone action, useful when quick thyroid hormone replacement is needed, may help patients who poorly convert t4 to t3. 10 sources indexed (2015–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Synthetic T3 that directly binds nuclear thyroid hormone receptors without requiring peripheral conversion. Activates gene transcription for proteins involved in oxygen consumption, basal metabolic rate, carbohydrate and lipid metabolism, and thermogenesis. Its direct action explains the rapid onset compared to T4-based therapies.7,2
Dosing & protocol.
Take on an empty stomach, ideally 30–60 minutes before food. Often dosed in divided doses (BID or TID) due to short half-life.
Full safety detail.
Side effects
- Tachycardia and palpitations
- Tremor
- Insomnia and nervousness
- Heat intolerance and sweating
- Weight loss
- Diarrhea
- Angina (in patients with coronary artery disease)
- Arrhythmias
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
4- 1Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysisPMIDBahl S, Taylor PN, Premawardhana LD et al. · The Journal of clinical endocrinology and metabolism · 2025
Bahl S, Taylor PN, Premawardhana LD et al.. Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis. The Journal of clinical endocrinology and metabolism. 2025
- 2Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysisPMIDNassar M, Hassan A, Ramadan S et al. · BMC endocrine disorders · 2024
Nassar M, Hassan A, Ramadan S et al.. Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis. BMC endocrine disorders. 2024
- 3LT4/LT3 Combination Therapy vs. Monotherapy with LT4 for Persistent Symptoms of Hypothyroidism: A Systematic ReviewPMIDVargas-Uricoechea H, Wartofsky L · International journal of molecular sciences · 2024
Vargas-Uricoechea H, Wartofsky L. LT4/LT3 Combination Therapy vs. Monotherapy with LT4 for Persistent Symptoms of Hypothyroidism: A Systematic Review. International journal of molecular sciences. 2024
- 4A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for HypothyroidismPMIDKraut E, Farahani P · Clinical and investigative medicine. Medecine clinique et experimentale · 2015
Kraut E, Farahani P. A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for Hypothyroidism. Clinical and investigative medicine. Medecine clinique et experimentale. 2015
Randomized controlled trials
2- 5Early effects of LT3 + LT4 combination therapy on quality of life in hypothyroid patients: a randomized, double-blind, parallel-group comparison trialPMIDHajtalebi F, Alaei-Shahmiri F, Golgiri F et al. · BMC endocrine disorders · 2025
Hajtalebi F, Alaei-Shahmiri F, Golgiri F et al.. Early effects of LT3 + LT4 combination therapy on quality of life in hypothyroid patients: a randomized, double-blind, parallel-group comparison trial. BMC endocrine disorders. 2025
- 6Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trialPMIDAzizi F, Amouzegar A, Abdi H et al. · Trials · 2025
Azizi F, Amouzegar A, Abdi H et al.. Treatment of hypothyroidism with levothyroxine plus slow-release liothyronine: a study protocol for a randomized controlled double-blinded clinical trial. Trials. 2025
Reference material
4- 7Jonklaas J et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24(12):1670-1751.Source linkedPMID
- 8Wiersinga WM et al. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55-71.Source linkedPMID
- 9Baskaran BS et al. Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review. Br J Clin Pharmacol. 2026.Source linkedPMID
- 10Jonklaas J, Bianco AC, Cappola AR et al.. Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid : official journal of the American Thyroid Association. 2021Source linkedPMID
Common questions.
Quick answers about Liothyronine, drawn from the data on this page.
What is Liothyronine?
Liothyronine is a synthetic form of triiodothyronine (T3), the most metabolically active thyroid hormone. It has a faster onset and shorter duration than levothyroxine and is sometimes used in combination with T4, for T3-only therapy in select cases, or for short-term TSH suppression in thyroid cancer diagnostic protocols. It is not considered first-line treatment for hypothyroidism.
What is Liothyronine used for?
Commonly cited benefits of Liothyronine include: Rapid onset of thyroid hormone action; Useful when quick thyroid hormone replacement is needed; May help patients who poorly convert T4 to T3; Used in thyroid cancer withdrawal protocols; Can be added to T4 therapy in select non-responders. NutriStack rates the overall evidence as moderate.
What is a typical dose of Liothyronine?
A typical adult dose of Liothyronine is 5–75 mcg daily in divided doses; combination therapy typically 5–15 mcg daily (as prescribed by your physician). The commonly recommended form is Oral tablet; IV formulation (Triostat) for myxedema coma. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Liothyronine?
Reported side effects include tachycardia and palpitations, tremor, insomnia and nervousness, heat intolerance and sweating, weight loss, diarrhea. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Liothyronine?
NutriStack rates this as Moderate, meaning several aligned RCTs or one large RCT plus supporting reviews. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Liothyronine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.